Global private equity and venture capital news and research

Amkey Ventures leads $20m Series A1 for for biopharmaceutical company Apexigen

8 Aug 2013

Amkey Ventures has led a $20m Series A round for biopharmaceutical startup Apexigen, which is developing antibody-based drugs for the treatment of life threatening and hard to treat diseases.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016